PARIS, France, June 21 /CNW Telbec/ - Sanofi-aventis announced today that the European Commission has granted marketing authorisation for ACOMPLIA(R) (rimonabant 20 mg/day) in all 25 European member states. ACOMPLIA(R), discovered and developed by sanofi-aventis, is the first in a new class of drugs called CB1 blockers. ACOMPLIA(R) is indicated as an adjunct to diet and exercise for the treatment of obese patients (BMI greater than or equal to 30kg/m2), or overweight patients (BMI greater than 27kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidaemia.
